Answer: Coadministration of atorvastatin and itraconazole is contraindicated because of the risk for myopathy
Use of atorvastatin with clarithromycin, azole antifungals, or lipid-modifying doses of niacin can increase the risk for myopathy. The dose of atorvastatin should not exceed 10 mg daily when taking cyclosporine, and caution is advised with doses higher than 20 mg daily when receiving treatment with clarithromycin or itraconazole.

Answer: Dose reduction may be required for persistent elevation in liver enzymes above 3 times the normal limit
Atorvastatin is linked to a dose-dependent risk for liver enzyme elevations that, for the most part, are not associated with jaundice or other signs/symptoms of liver dysfunction and resolve on dose reduction, drug interruption, or discontinuation of therapy. Liver function tests should be performed before and 12 weeks after both initiation of therapy and dose increases, and periodically thereafter. Dose reduction or dose discontinuation is advised for persistent elevations greater than 3 times the upper limit of normal.

Answer: Atorvastatin is not secreted into breast milk and may be administered to nursing mothers
Because of the potential for secretion in breast milk and the attendant risk for serious adverse events in nursing infants, mothers receiving atorvastatin should not breast-feed their infants. Also, atorvastatin should not be used in pregnancy because of risk to the fetus. According to the FDA, study data suggest an increased risk for nonfatal hemorrhagic stroke with use of 80-mg atorvastatin in patients without coronary heart disease who have had a stroke or transient ischemic attack in the past 6 months.